Context Therapeutics (NASDAQ:CNTX – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $6.00 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 188.46% from the stock’s current price.
Context Therapeutics Stock Performance
CNTX stock opened at $2.08 on Monday. Context Therapeutics has a one year low of $0.77 and a one year high of $2.75. The firm has a market cap of $156.00 million, a PE ratio of -1.56 and a beta of 2.31. The firm’s 50 day moving average price is $2.31 and its 200-day moving average price is $1.86.
Context Therapeutics (NASDAQ:CNTX – Get Free Report) last posted its earnings results on Wednesday, August 7th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04. Equities research analysts predict that Context Therapeutics will post -0.31 EPS for the current fiscal year.
Institutional Inflows and Outflows
Context Therapeutics Company Profile
Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
Read More
- Five stocks we like better than Context Therapeutics
- Why is the Ex-Dividend Date Significant to Investors?
- Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion?
- Golden Cross Stocks: Pattern, Examples and Charts
- Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge
- Investing In Automotive Stocks
- Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.